Reply to Yang et al.: Tocilizumab treatment in COVID-19 patients needs the assessment of the disease severity and timely intervention

doi:10.1073/pnas.2011616117

Comment

. 2020 Dec 1;117(48):30027-30028.

doi: 10.1073/pnas.2011616117. Epub 2020 Nov 12.

Reply to Yang et al.: Tocilizumab treatment in COVID-19 patients needs the assessment of the disease severity and timely intervention

Xiaoling Xu¹, Mingfeng Han², Tiantian Li³, Wei Sun², Dongsheng Wang³, Binqing Fu^{4

5}, Yonggang Zhou^{4

5}, Xiaohu Zheng^{4

5}, Yun Yang⁶, Xiuyong Li⁷, Xiaohua Zhang², Aijun Pan⁶, Haiming Wei^{8

5}

Affiliations

¹ Respiratory and Critical Care Medicine, The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital), Hefei 230000, People's Republic of China; ustcwhm@ustc.edu.cn xxlahh08@163.com.
² Respiratory and Critical Care Medicine, Anhui Fuyang Second People's Hospital, Fuyang 230000, People's Republic of China.
³ Respiratory and Critical Care Medicine, The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital), Hefei 230000, People's Republic of China.
⁴ Institute of Immunology and the Chinese Academy of Sciences Key Laboratory of Innate Immunity and Chronic Disease, School of Life Science and Medical Center, University of Science and Technology of China, Hefei 230000, People's Republic of China.
⁵ Hefei National Laboratory for Physical Sciences at Microscale, University of Science and Technology of China, Hefei 230000, People's Republic of China.
⁶ Intensive Care Unit, The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital), Hefei 230000, People's Republic of China.
⁷ Hemodialysis Center, Anhui Fuyang Second People's Hospital, Fuyang 236000, People's Republic of China.
⁸ Institute of Immunology and the Chinese Academy of Sciences Key Laboratory of Innate Immunity and Chronic Disease, School of Life Science and Medical Center, University of Science and Technology of China, Hefei 230000, People's Republic of China; ustcwhm@ustc.edu.cn xxlahh08@163.com.

PMID: 33184171
PMCID: PMC7720178
DOI: 10.1073/pnas.2011616117

Comment

Reply to Yang et al.: Tocilizumab treatment in COVID-19 patients needs the assessment of the disease severity and timely intervention

Xiaoling Xu et al. Proc Natl Acad Sci U S A. 2020.

. 2020 Dec 1;117(48):30027-30028.

doi: 10.1073/pnas.2011616117. Epub 2020 Nov 12.

Authors

Affiliations

¹ Respiratory and Critical Care Medicine, The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital), Hefei 230000, People's Republic of China; ustcwhm@ustc.edu.cn xxlahh08@163.com.
² Respiratory and Critical Care Medicine, Anhui Fuyang Second People's Hospital, Fuyang 230000, People's Republic of China.
³ Respiratory and Critical Care Medicine, The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital), Hefei 230000, People's Republic of China.
⁴ Institute of Immunology and the Chinese Academy of Sciences Key Laboratory of Innate Immunity and Chronic Disease, School of Life Science and Medical Center, University of Science and Technology of China, Hefei 230000, People's Republic of China.
⁵ Hefei National Laboratory for Physical Sciences at Microscale, University of Science and Technology of China, Hefei 230000, People's Republic of China.
⁶ Intensive Care Unit, The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital), Hefei 230000, People's Republic of China.
⁷ Hemodialysis Center, Anhui Fuyang Second People's Hospital, Fuyang 236000, People's Republic of China.
⁸ Institute of Immunology and the Chinese Academy of Sciences Key Laboratory of Innate Immunity and Chronic Disease, School of Life Science and Medical Center, University of Science and Technology of China, Hefei 230000, People's Republic of China; ustcwhm@ustc.edu.cn xxlahh08@163.com.

PMID: 33184171
PMCID: PMC7720178
DOI: 10.1073/pnas.2011616117

No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interest.

Comment on

Tocilizumab treatment in COVID-19: A single center experience.
Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J. Luo P, et al. J Med Virol. 2020 Jul;92(7):814-818. doi: 10.1002/jmv.25801. Epub 2020 Apr 15. J Med Virol. 2020. PMID: 32253759 Free PMC article.
Safety concerns regarding concomitant use of tocilizumab and glucocorticoids in COVID-19 patients.
Yang C, Liu E, Liu M. Yang C, et al. Proc Natl Acad Sci U S A. 2020 Dec 1;117(48):30025-30026. doi: 10.1073/pnas.2009253117. Epub 2020 Nov 12. Proc Natl Acad Sci U S A. 2020. PMID: 33184179 Free PMC article. No abstract available.

References

1. Yang C., Liu E., Liu M., Safety concerns regarding concomitant use of tocilizumab and glucocorticoids in COVID-19 patients. Proc. Natl. Acad. Sci. U.S.A. 117, 30025–30026 (2020). - PMC - PubMed
1. Xu X., et al. , Effective treatment of severe COVID-19 patients with tocilizumab. Proc. Natl. Acad. Sci. U.S.A. 117, 10970–10975 (2020). - PMC - PubMed
1. Sciascia S., et al. , Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19. Clin. Exp. Rheumatol. 38, 529–532 (2020). - PubMed
1. Alattar R., et al. , Tocilizumab for the treatment of severe coronavirus disease 2019. J. Med. Virol., 92, 2042−2049 (2020). - PMC - PubMed
1. Russell C. D., Millar J. E., Baillie J. K., Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet 395, 473–475 (2020). - PMC - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources

[1] Yang C., Liu E., Liu M., Safety concerns regarding concomitant use of tocilizumab and glucocorticoids in COVID-19 patients. Proc. Natl. Acad. Sci. U.S.A. 117, 30025–30026 (2020). - PMC - PubMed

[2] Yang C., Liu E., Liu M., Safety concerns regarding concomitant use of tocilizumab and glucocorticoids in COVID-19 patients. Proc. Natl. Acad. Sci. U.S.A. 117, 30025–30026 (2020). - PMC - PubMed

[3] Xu X., et al. , Effective treatment of severe COVID-19 patients with tocilizumab. Proc. Natl. Acad. Sci. U.S.A. 117, 10970–10975 (2020). - PMC - PubMed

[4] Xu X., et al. , Effective treatment of severe COVID-19 patients with tocilizumab. Proc. Natl. Acad. Sci. U.S.A. 117, 10970–10975 (2020). - PMC - PubMed

[5] Sciascia S., et al. , Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19. Clin. Exp. Rheumatol. 38, 529–532 (2020). - PubMed

[6] Sciascia S., et al. , Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19. Clin. Exp. Rheumatol. 38, 529–532 (2020). - PubMed

[7] Alattar R., et al. , Tocilizumab for the treatment of severe coronavirus disease 2019. J. Med. Virol., 92, 2042−2049 (2020). - PMC - PubMed

[8] Alattar R., et al. , Tocilizumab for the treatment of severe coronavirus disease 2019. J. Med. Virol., 92, 2042−2049 (2020). - PMC - PubMed

[9] Russell C. D., Millar J. E., Baillie J. K., Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet 395, 473–475 (2020). - PMC - PubMed

[10] Russell C. D., Millar J. E., Baillie J. K., Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet 395, 473–475 (2020). - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Reply to Yang et al.: Tocilizumab treatment in COVID-19 patients needs the assessment of the disease severity and timely intervention

Affiliations

Reply to Yang et al.: Tocilizumab treatment in COVID-19 patients needs the assessment of the disease severity and timely intervention

Authors

Affiliations

Conflict of interest statement

Comment on

Similar articles

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources